Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

2.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

388
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
388
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

254
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
254
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

311
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
311
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

260
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
260

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology.

Current heart failure reports·2026
Same author

GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction.

The American journal of cardiology·2026
Same author

Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.

European heart journal·2026
Same author

Beyond Chronological Age: Why Frailty Matters in Heart Failure.

European journal of heart failure·2026
Same author

A comprehensive review of cancer-induced cardiac wasting.

British journal of pharmacology·2026
Same author

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

The New England journal of medicine·2026
Same journal

Correction to: May Measurement Month 2017: screening for hypertension in Nigeria-Sub-Saharan Africa.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Optimizing protected PCI strategies in the setting of chronic kidney disease and advanced coronary artery disease: a clinical case-based discussion.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Protected percutaneous coronary intervention of complex distal left main disease with Impella CP™ support.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Contemporary evidence in protected percutaneous coronary intervention: a case-based review.

European heart journal supplements : journal of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jan 1, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.0K

Cardiac cachexia.

Alessia Lena1,2,3,4, Nicole Ebner5, Markus S Anker1,2,3,4

  • 1Division of Cardiology and Metabolism, Department of Cardiology, Charité-Campus Virchow Klinikum (CVK), Augustenburger Platz 1, 13353 Berlin, Germany.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|December 31, 2019
PubMed
Summary
This summary is machine-generated.

Cardiac cachexia, a metabolic condition in heart failure patients, worsens outcomes. New therapies and preventive strategies are crucial to combat this debilitating condition, especially in the elderly.

Keywords:
Cardiac cachexiaHeart failureSarcopaenia

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.6K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Related Experiment Videos

Last Updated: Jan 1, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.0K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.6K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Area of Science:

  • Metabolic disorders
  • Cardiology
  • Geriatrics

Background:

  • Cachexia is a complex metabolic disease characterized by a catabolic state.
  • It significantly impacts patients with chronic conditions like heart failure, particularly the elderly.
  • Cardiac cachexia affects approximately 10% of at-risk heart failure patients, worsening mortality, morbidity, and quality of life.

Purpose of the Study:

  • To highlight the urgent need for novel therapeutic interventions for cardiac cachexia.
  • To emphasize the importance of developing new preventive strategies for cachexia.
  • To underscore the impact of cardiac cachexia on patient outcomes.

Main Methods:

  • Review of existing literature on cachexia and cardiac cachexia.
  • Analysis of the prevalence and impact of cardiac cachexia in heart failure patients.
  • Evaluation of current treatment and prevention approaches.

Main Results:

  • Cardiac cachexia presents a significant clinical challenge in heart failure management.
  • Existing treatments like exercise and nutrition offer some benefit but are insufficient.
  • There is a critical unmet need for advanced therapeutic and preventive measures.

Conclusions:

  • Effective therapies and preventive strategies for cardiac cachexia are urgently required.
  • Addressing cachexia is essential for improving the prognosis and quality of life for heart failure patients.
  • Further research into novel treatments is paramount.